FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033851034> ?p ?o ?g. }

• W2033851034 endingPage "258" @default.
• W2033851034 startingPage "253" @default.
• W2033851034 abstract "•Current cancer chemotherapy results in high-grade toxicities that limit applicability. •Targeting drugs to tumor cells alleviates toxicity and promotes high local doses. •Cell targeted, virus-like drug nanocarriers escape renal filtration. •Insights into protein self-assembling allow the generation of drug-loadable viral mimetics. •The structural and functional versatility of proteins makes them ideal drug nanocarriers. High resistance and recurrence rates, together with elevated drug clearance, compel the use of maximum-tolerated drug doses in cancer therapy, resulting in high-grade toxicities and limited clinical applicability. Promoting active drug accumulation in tumor tissues would minimize such issues and improve therapeutic outcomes. A new class of therapeutic drugs suitable for the task has emerged based on the concept of virus-mimetic nanocarriers, or ‘artificial viruses’. Among the spectrum of materials under exploration in nanocarrier research, proteins offer unparalleled structural and functional versatility for designing virus-like molecular vehicles. By exhibiting ‘smart’ functions and biomimetic traits, protein-based nanocarriers will be a step ahead of the conventional drug–protein conjugates already in the clinic in ensuring efficient delivery of passenger antitumor drugs. High resistance and recurrence rates, together with elevated drug clearance, compel the use of maximum-tolerated drug doses in cancer therapy, resulting in high-grade toxicities and limited clinical applicability. Promoting active drug accumulation in tumor tissues would minimize such issues and improve therapeutic outcomes. A new class of therapeutic drugs suitable for the task has emerged based on the concept of virus-mimetic nanocarriers, or ‘artificial viruses’. Among the spectrum of materials under exploration in nanocarrier research, proteins offer unparalleled structural and functional versatility for designing virus-like molecular vehicles. By exhibiting ‘smart’ functions and biomimetic traits, protein-based nanocarriers will be a step ahead of the conventional drug–protein conjugates already in the clinic in ensuring efficient delivery of passenger antitumor drugs. directing ligand-driven nanoparticles to tumor cell types displaying specific membrane receptors used as targets. map of where compounds or drugs occur in the body of an animal or human being upon administration. time that a nanoconjugate remains detectable in the bloodstream. cells responsible for maintaining the tumor due to their capacity for self-renewal and differentiation. peptides able to translocate the cell membrane and to allow the internalization of associated compounds. the selective incorporation of nanoparticles into tumor tissue because of their irregularly fenestrated vessels and impaired lymphatic drainage. a distinctive label given by the US FDA to substances of microorganism to design that their addition to food is safe. inactivation of a drug through hepatic metabolism. responsible for phagocytosis and degradation of particular nanoparticle types. therapeutic molecule composed of a drug covalently bound to a nanoparticle. directing nanoparticles to tumors by virtue of the EPR effect. the attachment of polyethylene glycol (PEG) molecules to nanoparticles to alter their physicochemical properties. elimination from the body of drugs smaller than ∼7 nm by filtration through the kidney. arginine, glycine, and aspartic acid tripeptide frequently used in drug delivery and tissue engineering because of its ability to bind to specific cell surface integrins. endosomal transport of molecules from one side of the cell to the opposite side. peptides that show high affinity for proteins overexpressed at the surface of cancer cells and that are used as agents for drug targeting." @default.
• W2033851034 created "2016-06-24" @default.
• W2033851034 creator A5023851438 @default.
• W2033851034 creator A5029892045 @default.
• W2033851034 creator A5041180389 @default.
• W2033851034 creator A5041996335 @default.
• W2033851034 creator A5042249122 @default.
• W2033851034 creator A5057224975 @default.
• W2033851034 date "2015-05-01" @default.
• W2033851034 modified "2023-10-15" @default.
• W2033851034 title "Towards protein-based viral mimetics for cancer therapies" @default.
• W2033851034 cites W1963795982 @default.
• W2033851034 cites W1965063429 @default.
• W2033851034 cites W1967451220 @default.
• W2033851034 cites W1967637067 @default.
• W2033851034 cites W1969932115 @default.
• W2033851034 cites W1972541411 @default.
• W2033851034 cites W1975123157 @default.
• W2033851034 cites W1987604182 @default.
• W2033851034 cites W1998677002 @default.
• W2033851034 cites W2015212957 @default.
• W2033851034 cites W2015439707 @default.
• W2033851034 cites W2015526636 @default.
• W2033851034 cites W2016250986 @default.
• W2033851034 cites W2019678791 @default.
• W2033851034 cites W2021387568 @default.
• W2033851034 cites W2035443610 @default.
• W2033851034 cites W2041583645 @default.
• W2033851034 cites W2046308571 @default.
• W2033851034 cites W2048242283 @default.
• W2033851034 cites W2053879365 @default.
• W2033851034 cites W2054231318 @default.
• W2033851034 cites W2054745605 @default.
• W2033851034 cites W2060846993 @default.
• W2033851034 cites W2061775664 @default.
• W2033851034 cites W2062627275 @default.
• W2033851034 cites W2066117786 @default.
• W2033851034 cites W2069940872 @default.
• W2033851034 cites W2084039931 @default.
• W2033851034 cites W2088536552 @default.
• W2033851034 cites W2088722353 @default.
• W2033851034 cites W2105292533 @default.
• W2033851034 cites W2106567363 @default.
• W2033851034 cites W2108075741 @default.
• W2033851034 cites W2116539303 @default.
• W2033851034 cites W2117602118 @default.
• W2033851034 cites W2119752261 @default.
• W2033851034 cites W2126044151 @default.
• W2033851034 cites W2129217817 @default.
• W2033851034 cites W2129659516 @default.
• W2033851034 cites W2132184418 @default.
• W2033851034 cites W2135485684 @default.
• W2033851034 cites W2137634849 @default.
• W2033851034 cites W2139251684 @default.
• W2033851034 cites W2146205672 @default.
• W2033851034 cites W2153492724 @default.
• W2033851034 cites W2154165320 @default.
• W2033851034 cites W2156723154 @default.
• W2033851034 cites W2159304382 @default.
• W2033851034 cites W2161765631 @default.
• W2033851034 cites W2169961966 @default.
• W2033851034 cites W2172242904 @default.
• W2033851034 cites W2315525443 @default.
• W2033851034 cites W2327206682 @default.
• W2033851034 cites W2413110325 @default.
• W2033851034 cites W2475612538 @default.
• W2033851034 doi "https://doi.org/10.1016/j.tibtech.2015.02.007" @default.
• W2033851034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25805413" @default.
• W2033851034 hasPublicationYear "2015" @default.
• W2033851034 type Work @default.
• W2033851034 sameAs 2033851034 @default.
• W2033851034 citedByCount "62" @default.
• W2033851034 countsByYear W20338510342015 @default.
• W2033851034 countsByYear W20338510342016 @default.
• W2033851034 countsByYear W20338510342017 @default.
• W2033851034 countsByYear W20338510342018 @default.
• W2033851034 countsByYear W20338510342019 @default.
• W2033851034 countsByYear W20338510342020 @default.
• W2033851034 countsByYear W20338510342021 @default.
• W2033851034 countsByYear W20338510342022 @default.
• W2033851034 countsByYear W20338510342023 @default.
• W2033851034 crossrefType "journal-article" @default.
• W2033851034 hasAuthorship W2033851034A5023851438 @default.
• W2033851034 hasAuthorship W2033851034A5029892045 @default.
• W2033851034 hasAuthorship W2033851034A5041180389 @default.
• W2033851034 hasAuthorship W2033851034A5041996335 @default.
• W2033851034 hasAuthorship W2033851034A5042249122 @default.
• W2033851034 hasAuthorship W2033851034A5057224975 @default.
• W2033851034 hasBestOaLocation W20338510342 @default.
• W2033851034 hasConcept C114851261 @default.
• W2033851034 hasConcept C171250308 @default.
• W2033851034 hasConcept C18150654 @default.
• W2033851034 hasConcept C192562407 @default.
• W2033851034 hasConcept C2779820397 @default.
• W2033851034 hasConcept C2780035454 @default.
• W2033851034 hasConcept C71924100 @default.
• W2033851034 hasConcept C86803240 @default.
• W2033851034 hasConcept C89423630 @default.

• next